Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes.

TitleApparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes.
Publication TypeJournal Article
Year of Publication2015
AuthorsAppadurai, V, DeBarber, A, Chiang, P-W, Patel, SB, Steiner, RD, Tyler, C, Bonnen, PE
JournalMol Genet Metab
Volume116
Issue4
Pagination298-304
Date Published2015 Dec
ISSN1096-7206
KeywordsAfrica, Alleles, Americas, Asia, Cataract, Chenodeoxycholic Acid, Cholestanetriol 26-Monooxygenase, Cholestanol, Cholesterol, Chronic Disease, Computational Biology, Databases, Genetic, Diarrhea, Europe, Exome, Gene Frequency, Genes, Recessive, Humans, Incidence, Mutation, Xanthomatosis, Xanthomatosis, Cerebrotendinous
Abstract

Cerebrotendinous Xanthomatosis (CTX) is a treatable inborn error of metabolism caused by recessive variants in CYP27A1. Clinical presentation varies, but typically includes infant-onset chronic diarrhea, juvenile-onset bilateral cataracts, and later-onset tendinous xanthomas and progressive neurological dysfunction. CYP27A1 plays an essential role in side-chain oxidation of cholesterol necessary for the synthesis of the bile acid, chenodeoxycholic acid, and perturbations in this gene that reduce enzyme activity result in elevations of cholestanol. It is commonly held that CTX is exceedingly rare, but epidemiological studies are lacking. In order to provide an accurate incidence estimate of CTX, we studied the ExAC cohort of ~60,000 unrelated adults from global populations to determine the allele frequency of the 57 variants in CYP27A1 reported pathogenic for CTX. In addition, we conducted bioinformatics analyses on these CTX-causing variants and determined a bioinformatics profile to predict variants that may be pathogenic but have not yet been reported in the CTX patient literature. An additional 29 variants were identified that met bioinformatics criteria for being potentially pathogenic. Incidence was estimated based allele frequencies of pathogenic CTX variants plus those determined to be potentially pathogenic. One variant, p.P384L, previously reported in three unrelated CTX families had an allele frequency ≥ 1% in European, Latino and Asian populations. Three additional mutations had a frequency of ≥ 0.1% in Asian populations. CTX disease incidence was calculated excluding the high frequency p.P384L and separately using a genetic paradigm where this high frequency variant only causes classic CTX when paired in trans with a null variant. These calculations place CTX incidence ranging from 1:134,970 to 1:461,358 in Europeans, 1:263,222 to 1:468,624 in Africans, 1:71,677 to 1:148,914 in Americans, 1:64,267 to 1:64,712 in East Asians and 1:36,072 to 1:75,601 in South Asians. This work indicates CTX is under-diagnosed and improved patient screening is needed as early intervention prevents disease progression.

DOI10.1016/j.ymgme.2015.10.010
Alternate JournalMol. Genet. Metab.
PubMed ID26643207
PubMed Central IDPMC4767010
Grant ListR01 NS083726 / NS / NINDS NIH HHS / United States
R01NS083726 / NS / NINDS NIH HHS / United States